Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Neutral

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Neutral

B

Roivant Sciences Ltd. Common Shares (ROIV)

Pharmaceutical Preparations

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

CLARENDON HOUSE, 2 CHURCH STREET
HAMILTON HM11, D0

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/01/2021

Market Cap

8,315,924,890

Shares Outstanding

803,920,000

Weighted SO

803,921,356

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

KRYS --.--%

RXDX --.--%

AKRO --.--%

APLS --.--%

DAWN --.--%

PHAT --.--%

BPMC --.--%

LYRA --.--%

Beta

1.2420

Last Div

0.0000

Range

8.245-13.24

Chg

-0.0650

Avg Vol

5044212

Mkt Cap

8315924890

Exch

NASDAQ

Country

GB

Phone

44 2074 003 347

DCF Diff

12.9955

DCF

-1.7905

Div Yield

0.0000

P/S

52.5317

EV Multiple

-3.2345

P/FV

1.5223

Div Yield %

0.0000

P/E

1.7471

PEG

0.0479

Payout

0.0025

Current Ratio

27.9081

Quick Ratio

27.7500

Cash Ratio

26.4313

DSO

496.2361

DIO

694.9042

Op Cycle

1191.1403

DPO

567.0715

CCC

624.0689

Gross Margin

0.8872

Op Margin

30.5791

Pretax Margin

29.3720

Net Margin

29.9176

Eff Tax Rate

0.0071

ROA

0.7290

ROE

1.0272

ROCE

0.7707

NI/EBT

1.0186

EBT/EBIT

0.9605

EBIT/Rev

30.5791

Debt Ratio

0.0513

D/E

0.0613

LT Debt/Cap

0.0542

Total Debt/Cap

0.0578

Int Coverage

123.2845

CF/Debt

-2.1253

Equity Multi

1.1952

Rec Turnover

0.7355

Pay Turnover

0.6437

Inv Turnover

0.5253

FA Turnover

2.5067

Asset Turnover

0.0244

OCF/Share

-0.9624

FCF/Share

-0.9651

Cash/Share

7.7246

OCF/Sales

-4.4735

FCF/OCF

1.0027

CF Coverage

-2.1253

ST Coverage

-32.9548

CapEx Coverage

-364.2824

Div&CapEx Cov

-50.7864

P/BV

1.5223

P/B

1.5223

P/S

52.5317

P/E

1.7471

P/FCF

-11.7108

P/OCF

-11.6841

P/CF

-11.6841

PEG

0.0479

P/S

52.5317

EV Multiple

-3.2345

P/FV

1.5223

DPS

0.0000

Latest Headlines (EST)

Benzinga Jan 10, 15:12 Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations Benzinga Jan 02, 11:01 Assessing Roivant Sciences: Insights From 5 Financial Analysts GlobeNewswire Inc. Dec 20, 16:30 Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease GlobeNewswire Inc. Dec 20, 16:30 Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease Benzinga Nov 14, 14:00 8 Analysts Have This to Say About Roivant Sciences GlobeNewswire Inc. Oct 30, 17:30 Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

Revenue Product Segmentation